Endovia Health Sciences (EDVA) Proxy filing summary

Executive summary

• Special meeting set for Dec. 7, 2026, by virtual webcast; shareholders will vote on two share-issuance proposals, an 800 million-share authorization, a reverse split and adjournment.

• Record date Oct. 30, 2026; 11,412,554 common shares and 260,000 Series A-1 votes represented total voting power of 11,672,554.

Voting matters and shareholder proposals

• Proposal 1 seeks approval to issue up to 12,683,908 shares under Series D preferred stock and a $576,271 convertible note, beyond the 19.99% Exchange Cap; conversion may substantially dilute existing holders.

• Proposal 2 seeks approval for an initial issuance of up to 20 million ELOC shares above the Exchange Cap; the amended facility provides up to $135 million in total commitments, including prior sales.

• From July 1 to Oct. 22, 2026, 7,173,012 ELOC shares were sold for $2,299,568 gross proceeds; Proposal 2 approval is needed to access the amended facility.

• Proposals 1–5 each require a majority of votes cast; abstentions count against proposals. The Board unanimously recommends voting FOR each proposal.

• Proposal 5 would permit adjournment to solicit additional proxies if votes are insufficient; it is classified as routine for broker discretionary voting.

Board of directors and corporate governance

• Board may select a reverse-split ratio from 1-for-2 to 1-for-49 and may abandon implementation; if approved, the split must be effected before the meeting’s one-year anniversary.

• Current directors and executive officers as a group beneficially owned 986,250 shares, or 8.0%, as of the Oct. 30, 2026 record date.